Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coffea arabica methanolic extract (CAME) is a botanical extract derived from the beans of the *Coffea arabica* plant using methanol as a solvent. It is characterized by a high concentration of chlorogenic acid, which is considered its primary bioactive constituent. In preclinical research, CAME has demonstrated hepatoprotective effects, particularly in models of nonalcoholic steatohepatitis (NASH). Its mechanism of action involves the modulation of autophagy-related signaling pathways; specifically, it has been shown to inhibit the mechanistic target of rapamycin (mTOR) and enhance the expression of Microtubule-associated protein 1 light chain 3 beta (LC3-B). By regulating these signals, CAME helps restore autophagic flux, which is typically suppressed during the progression of liver damage in NASH.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on coffea arabica methanolic extract.